/SYVC

SYVC Stock - Synovics Pharmaceuticals, Inc.

Q: What is the analyst price target for SYVC?

Analyst price target information is not currently available for SYVC.

Q: What is SYVC's market cap?

Market capitalization information is not currently available for SYVC.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SYVC

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2004

FY2005

FY2006

FY2007

FY2008

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta83.17

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2008	FY2007	FY2006	FY2005	FY2004
Revenue	$25.96M	$23.47M	$10.52M	$8,192	$98,767
Gross Profit	$8.97M	$6.63M	$2.36M	$-37,097	$80,498
Gross Margin	34.6%	28.2%	22.4%	-452.8%	81.5%
Operating Income	$-2,483,465	$-10,264,471	$-3,619,186	$-1,911,565	$-786,415
Net Income	$-4,005,831	$-20,857,884	$-8,571,021	$-2,911,260	$-1,124,336
Net Margin	-15.4%	-88.9%	-81.5%	-35537.8%	-1138.4%
EPS	$-0.17	$-1.09	$-0.33	$-0.14	$-0.14

Company Overview

Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.

Frequently Asked Questions about SYVC

What is SYVC's current stock price?

Synovics Pharmaceuticals, Inc. (SYVC) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for SYVC?

No analyst price targets are currently available for this stock.

What sector is Synovics Pharmaceuticals, Inc. in?

Synovics Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is SYVC's market cap?

Synovics Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does SYVC pay dividends?

No, Synovics Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.